Head-to-head · Value Score
Vitara RX vs Shapely
Two GLP-1 deals, scored on the same six factors. Vitara RX lands a Value Score of 91, Shapely a 74. Here's who gives you the honest lower price — and where each one bites back.
Vitara RX
#4 · Grade A · Best Value
Est. first month
$99/mo
Save ~93% vs brand-nameShapely
#162 · Grade C+ · Watch List
Est. first month
From $99/mo (starting dose, compounded)
Save ~93% vs brand-nameThe verdict
Vitara RX takes it on Value Score, 91 to 74 — an est. $99/mo first month, with no teaser step-up baked in. Shapely isn't out of it: Shoppers who want insurance-accepted telehealth with compounded sema $99/mo and tirz $166/mo; CA, FL, NY, TX (expanding).
Deal-by-deal
The numbers that decide it. Green ✓ marks the stronger side on each line.
| Deal | Vitara RX | Shapely |
|---|---|---|
| Value Score | 91 (A) | 74 (C+) |
| Est. first month | $99/mo | From $99/mo (starting dose, compounded) |
| Save vs brand-name | ~93% | ~93% |
| Semaglutide | $99/mo | From $99/mo (starting dose, compounded) |
| Tirzepatide | $149/mo | From $166/mo (starting dose, compounded) |
| Both molecules | Yes | Yes |
| Pricing | Flat — no step-up | Watch |
| Coverage | 49 states | 4 states |
Factor by factor
The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.
Vitara RX
VitaraRx is a direct-to-consumer telehealth marketplace offering compounded semaglutide and tirzepatide at flat per-drug pricing across all doses — no membership or hidden fees.
Why it's a deal
- Among the lowest flat pricing in the market — $99/mo semaglutide and $149/mo tirzepatide, all doses same price
- Names its 503A pharmacy partner (Manifest Pharmacy, Greer SC) — strong supply-chain transparency
- LegitScript Certified
- Publishes the FDA compounded-medication disclaimer
- Covers 49 states with an explicit state list, not vague "most states" language
The fine print
- No corporate legal entity disclosed — only the trade name "VitaraRx"
- No named medical director — all clinical decisions made by independent providers (marketplace model)
- All sales final — no medication returns
- Per-vial mg quantity isn't clearly disclosed, making price comparisons harder
- Doesn't ship to Alaska
Shapely
Shapely is a GLP-1 telehealth platform founded by Dr.
Why it's a deal
- Founded by Dr. Justin Zaghi, MD/MBA — Harvard-trained, board-certified in internal medicine and obesity medicine, with Medical Director Ana Lisa
- Brand-name GLP-1s (Wegovy, Ozempic, Zepbound, Mounjaro, Foundayo) covered by major PPO and Medicare at copay
- Compounded semaglutide from $99/month with free 2-day shipping, syringes, and supplies included via 503A/503B pharmacy
- 1:1 registered dietitian (RDN) and monthly video provider visits included in every plan; unlimited chat and app support
- Cellular smart scale provided to qualifying patients for ongoing weight tracking throughout the program
The fine print
- Currently available only in California, Florida, New York, and Texas — 46 states unserved despite announced expansion
- Telehealth subscription ($99/mo self-pay, $49 first-month promo) is charged separately from compounded medication cost
- Labs not included — $75 flat rate for uninsured patients; baseline bloodwork may be required before prescribing
- No LegitScript certification found on any public page
- Compounding pharmacy partner not named publicly; 503A/503B status claimed but specific pharmacy undisclosed
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.
Neither one the right fit? Every program that outscores Vitara RX is ranked on the Vitara RX alternatives board, and the same list for the other side is on alternatives to Shapely.
More head-to-heads
Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.